Embody Review

Embody is the consumer brand on joinem.co. Modern Metabolic Medicine, Inc., a Delaware corporation, identifies itself as the legal operator. The site's current contact pages locate the business in Wilmington, Delaware, although the published postal code appears internally inconsistent and is not repeated here as verified headquarters data.

The legal documents separate administrative and clinical responsibility. Modern Metabolic Medicine operates the platform and coordinates records, scheduling, payment, and fulfillment. Independent clinicians affiliated with OpenLoop Health provide medical care and make prescribing decisions. Independent pharmacies dispense approved prescriptions.

Adults may use the service only in U.S. states or territories where the selected program is available. Embody does not publish the current state list. Its terms direct consumers to support for that information, so the service should not be described as nationally available for every treatment.

The process starts with an online assessment. The home page says an OpenLoop clinician meets with the individual after checkout to determine whether a prescription is appropriate. A clinician may request a brief virtual appointment when the submitted information is insufficient. Payment does not guarantee a prescription.

The current in-scope catalog maps to four active ingredients: compounded semaglutide and tirzepatide injections for weight management, plus compounded NAD+ and sermorelin. Three Katalys campaigns roll into this single provider review rather than producing separate NAD+, sermorelin, and GLP-1 brand pages.

The operative terms also mention semaglutide and tirzepatide gum. Those dosage-form variants stay under their active ingredients and outside the normalized cards because the current storefront collection presents injections. NAD+ injection and nasal spray also remain one medication identity instead of two therapies.

The non-promotional Embody Flat schedule lists semaglutide injection at $199 monthly, $169 per month for three months, $159 per month for six months, and $149 per month for twelve months. The corresponding totals are $199, $507, $954, and $1,788. Their unweighted monthly mean is $169.

The same terms add $100 per month for tirzepatide injection. That produces standard rates of $299, $269, $259, and $249 across the same terms, with totals of $299, $807, $1,554, and $2,988. Their unweighted monthly mean is $269.

Those averages are not current promotional quotes. The live Labor Day storefront lists semaglutide totals of $79 for one month, $228 for three, $438 for six, and $828 for twelve months. Those equal $79, $76, $73, and $69 per month, but they are excluded from the standard average because the site identifies them as a temporary promotion.

The promotional tirzepatide totals are $129 for one month, $378 for three, $738 for six, and $1,428 for twelve months, equal to $129, $126, $123, and $119 per month. The April terms instead describe a $149 first month followed by $399 monthly under Embody Start. No public offer rule reconciles those two schedules.

The home FAQ says pricing depends on four-, twelve-, twenty-four-, or fifty-two-week plans, while the storefront labels one-, three-, six-, and twelve-month supplies. These are roughly corresponding durations, but the mismatch adds avoidable ambiguity. The checkout should identify the exact billing cadence, amount charged now, renewal amount, and cancellation deadline.

Embody says price does not increase when the dose changes within the same medication. The terms separately reserve the possibility that the final charge varies with the prescribed medication and selected pharmacy. The review therefore does not claim a universal dose-independent guarantee beyond the provider's own statement.

The NAD+ landing page advertises compounded 500 mg and 1,000 mg injection options and also names a nasal spray. It displays a limited Labor Day price of $99 per month and says that price remains locked while enrollment continues. The page does not publish the ordinary rate, plan commitment, expiration, or a complete price-to-vial mapping.

The sermorelin page advertises one compounded injection per week at $99 per month during the same limited sale. It says no bloodwork is required and describes an online clinician evaluation. Dose, concentration, vial quantity, ordinary rate, and promotion expiration are not published in one operative treatment table.

All four normalized medication cards represent compounded prescriptions rather than FDA-approved products. FDA states that compounded drugs are not FDA approved and are not reviewed before marketing for safety, effectiveness, or quality. A facility's registration or regulation does not make an individual compounded product FDA approved.

Embody names Red Rock Compounding Pharmacy, HealthWarehouse, Precision Medicine, and Triad Rx as partners. The patient-specific dispensing pharmacy is not disclosed before intake, and some names, addresses, and linked domains do not align cleanly with current pharmacy branding. Patients should verify the actual dispensing entity and prescription label.

Medication, clinician review, care coaching, and shipping are described as bundled when applicable. Embody advertises free expedited or fast delivery, and the NAD+ page says one to two days. The terms provide no delivery guarantee and disclaim responsibility for independent-pharmacy or carrier delays.

Embody is a cash-pay, out-of-network service. Its terms say services, prescriptions, and laboratory work may not be covered by insurance. The home page advertises HSA and FSA acceptance, but account eligibility and reimbursement depend on the consumer's plan and are not guaranteed.

The current refund policy begins the subscription when payment is submitted and makes every purchase final at that point. Non-use, failure to complete intake, failure to attend a consultation, or refusal to accept a prescription does not create a refund right. Cancellation stops future billing only.

A cancellation request must arrive at least 72 hours before the next billing date. Multi-month and bundled plans are sold as one indivisible purchase and remain non-refundable for unused months, unused services, or medication that has not yet shipped. Timely cancellation stops the next renewal rather than unwinding the current term.

Provider-initiated medical disqualification is the sole stated refund exception. Even then, Embody deducts the value of consultations, asynchronous review, prescriptions, dispensed or shipped medication, and laboratory work. Damaged or incorrect medication may be replaced, but the policy does not offer a refund.

Support routes include support@joinem.co, (347) 269-4270, and patient-portal messaging for clinical questions. Embody says customer support and care-team messaging are available 24/7 and advertises unlimited appointments. It does not publish a response-time service level, and emergency care remains outside the platform.

The site discloses that some text, images, or media may be generated or enhanced with artificial intelligence and that actors or models may appear. It also says GLP-1 outcome claims are based on self-reported customer information rather than clinical-trial or public data. Those marketing outcomes are not treated as independent evidence of effectiveness.